From the President’s Desk
Ryan Vandrey, Ph.D.

Happy summer Division 28!

I hope this newsletter finds everyone doing well. I switched up my profile picture this issue to share some of the silliness that I engaged in early in the COVID-19 pandemic as a way to pass the time when research was largely shut down, schools were closed, and attending conferences in person was completely out of the question. With those important facets of life removed, my kids and I would give each other crazy haircuts, make up games, and do anything to remain sane while on lockdown in Maryland.

Well... I’m writing this column in late July and the annual APA convention is right around the corner and this will be the first face-to-face APA meeting since 2019. Division 28 programming at the convention is packed with goodies and I really hope to see a lot of you in Minneapolis! Jake Borodovsky has been relentless in preparing for the convention and deserves kudos for not only preparing a stellar line-up of symposia, workshops, and poster sessions, but also coordinating a number of social events at the meeting as well. I’m not going to spoil any surprises as he details all the goods in his column below.

Other excitement relates to movement on the Division 28 Executive Committee. Earlier this year Jermaine Jones was elected to succeed Tom Gould as the division president and Cecilia Bergeria was elected to succeed Eric Donny as Member-At-Large. Jermaine will begin his term as President-Elect and Cecilia will begin her term as Member-At-Large in January. Many thanks to Micky Koffarnus and Dennis McBride for running for office, these were both tightly contested elections. We also have a few mid-year changes to the Executive Committee to report. Tadd Schneider has taken on the role of Archivist from Justin Strickland, and Jermaine Jones has volunteered to fill the vacant role of division liaison to the Board of Scientific Affairs. There are a few more positions that remain to be filled by the end of the year, so anyone interested in a leadership position in Division 28, please reach out to me directly (rvandrey@jhmi.edu).

Continued on page 2...
Table of Contents

From the President’s Desk .................................................................................................................. 1
Table of Contents ............................................................................................................................... 2
A Very Special Thank You to our Corporate Affiliates ................................................................. 4
And another Warm Thank You! ........................................................................................................ 4
2022 APA Convention Update ........................................................................................................ 5
Division 28 Social Hour .................................................................................................................... 6
Nicotine Policy: Is it Time for a Change? ........................................................................................ 7
Division 28 Research Spotlight ....................................................................................................... 8
New Fellows Nominations ................................................................................................................. 9
Upcoming Events ............................................................................................................................. 9
Psychopharmacology and Substance Use News Editorial Policy .................................................. 9
Welcome to our New Division 28 Members! .................................................................................. 10
Division 28 Membership Information ............................................................................................ 10
Experimental and Clinical Psychopharmacology .......................................................................... 11
Experimental and Clinical Psychopharmacology .......................................................................... 12
Training and Employment Announcements .................................................................................... 13
Division 28 Executive Committee .................................................................................................. 18

Division 28 has also continued to work diligently to address issues related to equity, diversity, and inclusion (EDI). This has been a focus of the division for several years, and I think really was pushed to the forefront during Wendy Lynch’s term as president. President-Elect Tom Gould, EDI committee member Meredith Berry, and I have attended several meetings with the APA EDI office this year as APA works to roll out a framework for ensuring equal opportunity and inclusivity in psychology. This is expected to be disseminated shortly after the APA convention this fall.

Also, Division 28 (along with Divisions 12, 45, 50) has begun implementation of an APA-funded mentoring program called Promoting Underrepresented Minorities in Psychology (PUMP). Division members should have received an e-mail recently soliciting participation in this program. I encourage all to consider participating as mentorship is needed across the career spectrum. If you did not receive the e-mail and would like to participate, please let me know (rvandrey@jhmi.edu).

The central APA office has also been ramping up engagement of divisions for advocacy efforts this year. One of the greatest benefits of membership in APA, and in Division 28, is the platform it provides for making our voices heard in Washington DC. Annually, APA engages congress to increase funding for science, to ensure that experts from our division contribute to key conversations related to major public health problems like the enduring opioid crisis, and the association coordinates opportunities for members to meet with their elected representatives and senators in congress. This year I have been meeting with APA employees to help improve the bi-directional communications between APA and the division related to advocacy concerns of the division, and also to ensure that APA is aware of the content expertise our members have that can assist APA with its own advocacy initiatives. I encourage each of you to speak to members of congress about issues you care about broadly, but especially issues that are important to psychological science and the agenda of the division. If there are advocacy issues that you would like to make sure are addressed by APA, please let me know. Similarly, if you believe you can offer assistance related to current APA advocacy topics (https://www.apa.org/news), let me know or check out the APA advocacy guide here: https://www.apaservices.org/advocacy/get-involved.
The last thing I want to address in this column is membership. I joined APA and Division 28 in 2001 and have served the division in a number of roles over the years. In that time, membership engagement and retention has always been an issue. Part of the problem with this is that I feel that a lot of the benefits of membership are somewhat unseen (see paragraph above related to APA advocacy). The other is that APA must compete with a host of other professional organizations, many of which are probably more specifically related to our professional areas of interest (e.g. organizations focused on alcohol, nicotine, cannabis, opioids, behavior analysis, etc.). When I discuss this with people, I often hear folks say something like APA is too big, the focus is too broad, the convention is overwhelming. I would like to appeal to this view by saying that I have actually found intense intimacy in APA, and especially within Division 28. Though the APA convention often has around 10,000-12,000 attendees, Division 28 runs a single-track program every year dedicated to cutting edge science on psychopharmacology and substance use. Over the years, I have found senior scientists who are near impossible to approach at meetings like CPDD or SRNT, easy to access and far more engaging at APA meetings. I have also found Division 28 social events at the conference to be more intimate and manageable than a lot of other conventions.

The executive committee has been brainstorming ways to 1) improve the visibility of the benefits of membership, 2) improve the delivery of relevant content of interest, without spamming your inbox with every nugget of information we come across, 3) continue to build outstanding convention programming, and 4) better brand our identity. In my last column, I mentioned the initiative to bolster the Division 28 presence on social media. If you are not already doing so, please follow the division on Twitter (@APADiv28), our primary social media platform. Tag us on your posts related to the division, submit your new publications to be highlighted on the division account, and please post updates, reactions and pictures from the convention. We will also be continuing to post new member profiles, so please follow us to learn more about your fellow psychologists!

My final thought related to membership is simply to ask that each of you take a moment to check to see if you renewed your membership this year. APA is a bit funky when it comes to this because, as an organization, it allows members to "lapse" in their dues for a year without much noise. I have been guilty of inadvertently failing to renew my membership because I simply didn't have the bandwidth to handle it when I got the renewal e-mail. We all get busy and sidetracked. I say this because as of right now, out of 929 current members of the division, 328 have not renewed their dues this year. That is 35% attrition! In scrolling through the list of names who have not renewed this year, I see a lot of long-time members, a lot of friends and colleagues whom I expect just let this slip unintentionally. Please take a moment to log into your APA account and check to see if you are up to date on your dues. Also, as a reminder, one can be a member of Division 28 without being a current member of APA. Dues for the division are modest, but they keep this organization afloat. Last, please encourage your colleagues, mentees, and students to join the division!

With that, I thank you all for reading, for your membership, and your service. Still debating whether to let the kids give me one last haircut before leaving for the conference... hope to see everyone in Minneapolis!

-Ryan
A Very Special Thank You to our Corporate Affiliates

For more on Friends Research Institute, please visit their website: https://friendsresearch.org/

For more on Ashley, please visit their website: https://www.ashleytreatment.org/

For more on Harrison assessments, please visit their website: https://www.harrisonassessments.com/

For more on Med Associates Inc., please visit their website: https://www.med-associates.com/

And a Warm Thank You!

We would also like to extend a warm thank you and express our gratitude to Dr. William Stoops Endowed Fund at Blue Grass Community Foundation
The 130th annual APA convention in Minneapolis is just around the corner!

This year's Division 28 programming features all kinds of exciting scientific advances in our understanding of a variety of substances/compounds (both new and old) and novel methodological applications and therapeutic approaches. To see all of the amazing events we have lined up, take a look at the Division 28 program here. I'm certain that this year you'll find tons of opportunities to learn, engage with friends and colleagues, and overall have a great time in Minneapolis.

Note that the full APA 2022 program is only available in the APA Convention mobile app, so I'd strongly recommend downloading the app to navigate the conference.

I'd also like to congratulate our phenomenal award winners who will be presenting their research starting at 8:00 am Thursday, 8/4.

- Cassandra L. Boness, PhD: Outstanding Dissertation Award
- Lorenz S. Neuwirth, PhD: Young Psychopharmacologist Award
- John M. Roll, PhD: MED Associates Brady/Schuster Award

Please be sure to attend the NIDA/NIAAA ECI Travel Award Poster Session and Social (co-sponsored by Division 28) to support and celebrate the early career Division 28 members being recognized for their incredible work! The event will take place on Friday, August 5, 4:00 pm-5:50 pm (Nicollet Ballroom AB, Main Level).

Division 28 is also hosting a catered social event at the Union Rooftop Restaurant/Bar (Friday, Aug 5th at 7:30, located at 731 Hennepin Ave). We’re spreading the word to other divisions working in substance use-related fields so that we can make this a great opportunity to network and make new friends. If you’re not yet a member of Division 28 and you’re interested in joining, this is a perfect opportunity! I’d like to specifically thank Andrea Vásquez Ferreiro and Madison Murray for their terrific job in making this event happen.

Be sure to check out our Twitter handle (@apadiv28) and some of the program highlights being posted.

As always, please reach out with any questions: Jacob.Borodovsky@dartmouth.edu

Looking forward to seeing everyone!
Division 28 Social Hour
Andrea Vásquez Ferreiro and Madison Murray

Are you attending the upcoming APA Conference in Minneapolis? Division 28 invites members and their colleagues interested in psychopharmacology and substance use to join us for a Social Hour. The event takes place on August 5th at 7:30pm at the Union Rooftop. Appetizers will be provided at the beginning along with a cash bar for the duration of the event.

This will be a fun event to catch up with colleagues, find future mentors and mentees, and unwind after a full day at the conference! We hope to see you there!
Nicotine Policy: Is it Time for a Change?  
Eric C. Donny, Ph.D.

Members of Division 28 have long been leaders in the science of drugs and behavior. While much of our collective research has focused on the evaluation of treatments for use of opiates, cocaine and other illicit drugs, we now have an opportunity to shape policy related to the deadliest of all drug use behaviors – smoking. Cigarettes remain the leading cause of preventable death in the U.S. and many other countries around the world. While we may not see it in our daily lives, it is still quite prevalent, especially in the communities public health has often left behind. As I near my 30th year of conducting nicotine and tobacco research, I remain perplexed as to how/why we allow the sale of a product that is both addictive and deadly. It does not have to be this way.

In June, the Biden administration announced that regulations targeting the addictive nature of cigarettes would be a priority, calling on the FDA to release a proposed rule by May of 2023 to set maximum levels for nicotine that would render cigarettes minimally addictive. This announcement revived one of the pillars of the Comprehensive Plan for Tobacco and Nicotine Regulation that was announced by former FDA Commissioner Dr. Scott Gottlieb in 2017 and led to an Advanced Notice of Proposed Rule-Making on nicotine product standards released by the FDA in 2018. Over the past 4 years, that vision seemed to fade, despite studies demonstrating that when participants in randomized clinical trials switch to very low nicotine content cigarettes, cigarettes per day, dependence and biomarkers of smoke exposure decrease and quit attempts and cessation increase. This research should have put to rest some of the concerns about nicotine reduction (e.g., that smokers will just compensate – they don’t). So why did it fade? Will this time be any different?

Concerns remain - most notably that reducing nicotine will drive a spike in illicit markets to meet the demand for full nicotine content cigarettes. Opponents of nicotine reduction point to the fact that participants in clinical trials “cheat” by supplementing their low nicotine cigarettes with commercially available normal nicotine cigarettes. Is this the canary in the coalmine for a massive illicit market? Another pillar of the Comprehensive Plan may determine the answer - making less harmful alternative sources of nicotine widely available. The FDA has made clear that their intention is not to prohibit nicotine, but rather to break the link between the nicotine use and the devastating death and disease caused by smoking. Consistent with this view, the FDA has recently approved a few products that they deemed “appropriate for the protection of the public health” although, to date, many other applications have been denied because regulators determined they failed to meet this standard. As a father of two teenagers and the son of a mother who still smokes, I appreciate the need to minimize access to and appeal of e-cigarettes to youth while maximizing the potential benefit that tobacco harm reduction offers for adult smokers.

As scientists, citizens, and members of Division 28 each of us has an important decision to make. Do we advocate for or against a policy to reduce nicotine in cigarettes? And what role do non-combusted alternatives play in our decision? Personally, I have come to the conclusion that neither nicotine reduction nor alternative sources of nicotine, by themselves, is sufficient to address the problem – not if we want to act with the urgency proportionate to the harm caused by smoking. But I am one voice. Regardless of your view, I urge you to join the discussion.
Division 28 Research Spotlight
Meredith Berry, Ph.D. & Neo Gebru, Ph.D., MPS, M.S., CHES

Dr. Jillian Rung is a basic and translational experimental psychologist with a background in behavioral economics and behavior analysis. She has conducted extensive research on delay discounting in both humans and non-human animals with a particular interest in developing behavioral economic-based methods to reduce harmful substance use. Across two NIH T32 postdoctoral fellowships, she developed expertise in substance use research and subsequently narrowed her focus to alcohol use. She is now completing the final stages of her training in alcohol research proper with an emphasis in broadening her skillset in remote assessment methods and community-based research. Dr. Rung has authored and co-authored 30 peer-reviewed papers, reviewed for over 20 different scientific journals, the NSF, and an NIH-funded research center.

Her recently awarded NIAAA K Award focuses on evaluating whether state-level fluctuations in delay discounting and alcohol demand predict alcohol use in the field. To this end, she will be using ecological momentary assessment to measure delay discounting and alcohol demand, as well as self-reported alcohol consumption. Establishing this predictive relationship is important because most research, and in particular that involving delay discounting, has focused on connections between what might be better considered trait level measures of these behavioral economic indices and alcohol use and/or problems. Having a clearer understanding of the level(s) (i.e., trait vs. state) at which discounting and demand precede and predict alcohol use in the field will speak to the potential utility of intervening on these processes at various temporal levels.

We wanted to learn more about the impressive research Dr. Rung was conducting, and her approach to science. Dr. Rung was kind enough to answer a few questions we had on what excites her about research. Thank you Dr. Rung, for your contributions to the field and for allowing us to highlight your work!

What got you interested in your line of research? The very clear real-world applicability of behavioral economic phenomena, and how sometimes “simple” changes can have such drastic impacts on behavior, both at the individual and population level. There still seems to be a lot of untapped potential in terms of leveraging these phenomena—things like discounting and loss aversion, to name a few—to address harmful alcohol use. Being able to investigate, understand, and develop ways we can do so is exciting. The applied value of my work is incredibly important to me.

What are you most excited about the future directions of your work? It’s hard to pick just one or two things! In terms of my K, I am planning to develop an interventional study that is informed by the results of the aims; and for another research line I’ve been developing, that’s transitioning to evaluating the effects of a manipulation on real (vs. hypothetical) alcohol consumption. Broadly speaking, it’s moving things along the basic to applied spectrum.

Anything else you want to include? A picture of my beloved pandemic cat, Bismarck. He’s kept me sane the last few years and deserves recognition for being the best boy.
New Fellows Nominations
Mikhail Koffarnus, Ph.D.

Division 28 is seeking nominations for new Fellows. As described by APA, “Fellow status is an honor bestowed upon APA members who have shown evidence of unusual and outstanding contributions or performance in the field of psychology. Fellow status requires that a person’s work has had a national impact on the field of psychology beyond a local, state, or regional level. A high level of competence or steady and continuing contributions are not sufficient to warrant fellow status. National impact must be demonstrated.”

In Division 28 a successful nominee will typically be 10-15 years post-doctorate, have a minimum of 30 publications and a track record of external funding, and can document national impact of her or his research.

If you would like to nominate a colleague for consideration for Fellow status, please send her or his CV and contact information to the address below. You may also nominate somebody who is already an APA Fellow (with relevance to our Division), but who is not yet a Fellow of Division 28. Self-nominations are also welcomed.

Contact Information for Fellow Nominations:
Mikhail Koffarnus, Ph.D.
Division 28 Fellows Chair
Email: koffarnus@uky.edu

Upcoming Events
Meredith Berry, Ph.D.

2022 Annual APA Convention

The 130th annual American Psychological Association convention is scheduled to be held in-person, August 4-6, 2022. Please visit https://convention.apa.org/ for more details and registration information.

Please visit the APA Division 28 News and Events section of our website to learn about other upcoming events and meetings. To submit an announcement of an upcoming event to the website and/or newsletter, please send all information or flyers to the newsletter editor, Meredith Berry (mberry@ufl.edu).

Psychopharmacology and Substance Use News Editorial Policy

Psychopharmacology and Substance Use News is a thrice-yearly publication of Division 28. It is devoted to keeping its members informed about the activities of Division 28 and to news and comments concerning all aspects of psychopharmacology and substance use. Articles, comments, announcements, and advertisements should be sent to the editor, Meredith Berry (mberry@ufl.edu).

You can also read content from archived Division 28 newsletters here.
Welcome to our New Division 28 Members!

We are very stoked to welcome several new members to the division recently! We are excited to get to know our new members. If you are a new member and would like to be introduced in the newsletter, please contact Brent Kaplan (brentkaplan@uky.edu).

Division 28 Membership Information

Brent Kaplan, Ph.D.

Individual Memberships

Division 28 is committed to:

- Basic and Applied Research
- Undergraduate, Graduate, and Postdoctoral training
- Evidenced-based Clinical Practice
- Public Service and Advocacy

We accept APA members and non-members, and have different membership levels available for students, early career psychologists (terminal degree within the past 7 years), and regular members.

Members receive a thrice-yearly newsletter, and are eligible for 1 of 3 annual awards (Outstanding Dissertation, Early Career Psychopharmacologist, Med Associates Brady/Schuster Award). See the previous award winners at our Division 28 awards page!

Please consider joining or renewing your membership this year. Contact our membership chair Brent Kaplan (brentkaplan@uky.edu) or visit our Division 28 membership page on our website for more information!

Corporate Affiliate Memberships

Corporate contributions support efforts in research, practice, and education. A membership contribution of $1000 is tax deductible.*

Division 28 is pleased to offer the following benefits to our corporate affiliate members:

- Access to thrice yearly newsletter
- Acknowledgement of support with corporate logo in newsletter
- Newsletter acknowledgement hyperlinked to corporate website, and available to all through newsletter posting on the Division 28 website
- Recognition of corporate support at annual APA membership meeting
- Liaison(s) eligible to subscribe to Division members-only listserv
- Liaison(s) participation in active and growing Division 28 social media presence
- Receive overview of relevant programming at APA convention

Please refer to the website for questions regarding Division 28 Corporate Affiliate Membership or contact:

Dr. Ryan Vandrey (Division 28 President) at rvandrey@jhmi.edu

Or

Dr. Will Aklin (Division 28 Treasurer) at aklinwm@nida.nih.gov

*This is the recommended level of support. Any corporate contributions are tax exempt, and our tax number will be supplied upon request. Other levels of support are available.
## TABLE OF CONTENTS: 2022 | VOLUME 30 | ISSUE 2 (April)

Editor: William Stoops, Ph.D.

1. The effects of artificially induced proestrus on heroin intake: A critical role for estradiol.  
   Pages 127-131. Smith, Mark A.; Ethridge, Sarah B.; Gibson, Abigail N.; Schmidt, Karl T.; Sharp, Jessica L.

   Pages 132-140. Smit, Tanya; Chavez, JeanFelix; Garey, Lorra; Mayorga, Nubia A.; Rogers, Andrew H.; Zvolensky, Michael J.

3. Validity of the alcohol purchase task with United States military personnel.  
   Pages 141-150. Pebley, Kinsey; Murphy, James G.; Wang, Xin-Qun; Talcott, G. Wayne; Klesges, Robert C.; McDevitt-Murphy, Meghan E.; McMurry, Timothy L.; Little, Melissa A.

   Pages 151-158. Linden-Carmichael, Ashley N.; Calhoun, Brian H.

5. Behavioral economic interactions between cannabis and alcohol purchasing: Associations with disordered use.  
   Pages 159-171. Dolan, Sean B.; Spindle, Tory R.; Vandrey, Ryan; Johnson, Matthew W.

6. Verbal behavior related to drug reinforcement in polysubstance cannabis users: Comparison across drugs.  
   Pages 172-179. Cox, David J.; Johnson, Matthew W.

7. Methamphetamine administration dose effects on sexual desire, sexual decision making, and delay discounting.  

   Pages 194-208. Smith, Aaron P.; Kelly, Thomas H.; Lile, Joshua A.; Martin, Catherine A.; Ramirez, Miranda P.; Wesley, Michael J.

9. An evaluation of the effect of methylphenidate on working memory, time perception, and choice impulsivity in children with ADHD.  
   Pages 209-219. Campez, Mileini; Raiker, Joseph S.; Little, Kelcey; Altszuler, Amy R.; Merrill, Brittany M.; Macphee, Fiona L.; Gnagy, Elizabeth M.; Greiner, Andrew R.; Musser, Erica D.; Coles, Erika K.; Pelham, William E.

10. Relapse after incentivized choice treatment in humans: A laboratory model for studying behavior change.  
    Pages 220-234. Thrailkill, Eric A.; Alcalá, José A.

11. The acute dose and baseline amplitude-dependent effects of CDP-choline on deviance detection (MMN) in chronic schizophrenia: A pilot study.  
    Pages 235-248. Aidelbaum, Robert; Labelle, Alain; Choueiry, Joëlle; Knott, Verner.

    Pages 249-252. Montiel, Catalina; Newmark, Rebecca L.; Clark, Crystal T.
# Experimental and Clinical Psychopharmacology

**TABLE OF CONTENTS: 2021 | VOLUME 30 | ISSUE 3 (June)**

**Editor:** William Stoops, Ph.D.

1. **Acute nicotine reinforcement requires ability to discriminate the stimulus effects of nicotine.**
   Pages 253-268. Perkins, Kenneth A.

2. **Tobacco cigarette smokers who endorse greater intolerance for nicotine withdrawal also report more severe insomnia symptoms.**
   Pages 269-278. Lape, Emma C.; LaRowe, Lisa R.; Zale, Emily L.; Gellis, Les A.; Park, Aesoon; Ditre, Joseph W.

3. **The effect of area-level disadvantage and race on smoking abstinence in a clinical trial.**
   Pages 279-286. Nollen, Nicole L.; Mayo, Matthew S.; Saint Onge, Jarron M.; Scheurmann, Taneisha S.; Cox, Lisa Sanderson; Chae, David; Leavens, Eleanor; Ahluwalia, Jasjit S.

4. **Randomized controlled trial of motivational interviewing for alcohol and cannabis use within a predominantly Hispanic adolescent sample.**
   Pages 287-299. Feldstein Ewing, Sarah; Bryan, Angela D.; Dash, Genevieve F.; Lovejoy, Travis I.; Borsari, Brian; Schmiege, Sarah J.

5. **The prospective interactive effects of alcohol expectancies and subjective response on future drinking behavior.**
   Pages 300-312. Waddell, Jack T.; Corbin, William R.; Chassin, Laurie; Anderson, Samantha F.

6. **Episodic future thinking as a brief alcohol intervention for heavy drinking college students: A pilot feasibility study.**
   Pages 313-325. Voss, Andrew T.; Jorgensen, Margaret K.; Murphy, James G.

7. **Future thinking to decrease real-world drinking in alcohol use disorder: Repairing reinforcer pathology in a randomized proof-of-concept trial.**
   Pages 326-337. Athamneh, Liqa N.; Brown, Jeremiah; Stein, Jeffrey S.; Gatchalian, Kirstin M.; LaConte, Stephen M.; Bickel, Warren K.

8. **(Non-) impact of task experience on behavioral economic decision-making.**
   Pages 338-350. Strickland, Justin C.; Bolin, B. Levi; Marks, Katherine R.

9. **Factors impeding switching from clozapine to paliperidone among patients with chronic schizophrenia—A retrospective cohort study.**
   Pages 351-358. Li, Dian-Jeng; Lin, Ching-Hua; Chen, Cheng-Chung.

10. **Correlates of the nicotine metabolite ratio in Alaska Native people who smoke cigarettes.**
    Pages 359-364. Vogel, Erin A.; Benowitz, Neal L.; Skan, Jordan; Schnellbaecher, Matthew; Prochaska, Judith J.

11. **Measurement of cigarette smoking: Comparisons of global self-report, returned cigarette filters, and ecological momentary assessment.**
    Pages 365-370. Ozga, Jenny E.; Bays, Colleen; Haliwa, Ilana; Felicione, Nicholas J.; Ferguson, Stuart G.; Dino, Geri; Blank, Melissa D.

12. **E-liquid purchase as a function of workplace restriction in the experimental tobacco marketplace.**
    Pages 371-377. Freitas-Lemos, Roberta; Stein, Jeffrey S.; Pope, Derek A.; Brown, Jeremiah; Feinstein, Marc; Stamborski, Kelsey M.; Tegge, Allison N.; Heckman, Bryan W.; Bickel, Warren K.
Training and Employment Announcements

VERMONT CENTER ON BEHAVIOR AND HEALTH POSTDOCTORAL RESEARCH FELLOWSHIPS

The Vermont Center on Behavior and Health (VCBH), located at the University of Vermont (UVM) Larner College of Medicine (LCOM) announces THREE NIH postdoctoral research fellowship opportunities in our internationally-recognized center of excellence in tobacco and substance use disorder research.

Working with Dr. Stacey Sigmon, the fellow will help to lead ongoing randomized clinical trials evaluating low-barrier, technology-assisted buprenorphine treatment for individuals with opioid use disorder (OUD), as well as develop new research opportunities aimed at expanding OUD treatment access in rural, underserved areas.

Working with Dr. Diann Gaalema, the fellow will participate in the conduct of an ongoing NIDA/FDA-funded trial on the use of tobacco in vulnerable populations, including people with affective disorders, as well as work on and develop new research opportunities within the area of tobacco use in cardiac patients.

Working with Dr. Andrea Villanti, the fellow will assist with ongoing population studies related to youth and young adult tobacco and substance use and vaping prevention, and randomized controlled trials of nicotine messaging. The fellowship will include secondary analysis of cohort and trial data to inform public health programs and policy, with opportunities to develop new research projects in ongoing and pilot studies.

Drs. Sigmon, Gaalema and Villanti, VCBH colleagues, and our 30-year training program have an exceptional track record of helping fellows to establish successful careers as independent investigators.

Eligibility: Applicants must have completed their training in psychology or a related discipline and be U.S. citizens or permanent residents. Outstanding trainees are selected on the basis of scholastic record, productivity and commitment to a career in substance use disorder research. Individuals must be highly motivated, possess initiative, and have a strong desire to learn and expand their interests and expertise.

Appointment: 2-3 yrs

Benefits: Stipend, medical insurance coverage, and travel funds supported by NIH Institutional Training Awards.

To apply: Send application form (downloaded from VCBH website), a cover letter, curriculum vitae, statement of research interests, and 3 letters of reference to: Dr. Sarah Heil (sarah.heil@uvm.edu). Please indicate which faculty member(s) you are interested in working with in your cover letter.

For more information: Contact Ms. Nicole C. Twohig (Nicole.twohig@uvm.edu) or visit our website (www.med.uvm.edu/behaviorandhealth).

About us: VCBH, established in 2013, is an interdisciplinary center of research excellence committed to investigating relationships between personal behavior patterns (i.e., lifestyle) and risk for chronic disease and premature death. Unhealthy, or risk behaviors, are overrepresented among socioeconomically disadvantaged populations and are major contributors to the problem of health disparities. VCBH’s work seeks to develop effective interventions and policies to promote healthy behavior. The VCBH resides within the UVM LCOM Department of Psychiatry, with additional investigators, collaborators, and advisors across 15 LCOM academic departments, seven UVM colleges, and five other universities. The VCBH is further strengthened by interdisciplinary collaborations with key community healthcare leaders and distinguished scientific advisory panels.

Burlington, Vermont is located in the beautiful Lake Champlain region and has continually been voted one of the nicest cities in which to live as well as one of America’s most “fit” cities due to the four seasons of outdoor activities. Burlington is a great place for families, boasting excellent schools, a culturally-rich environment, and close proximity to Boston and Montreal.

The University is especially interested in candidates who can contribute to the diversity and excellence of the academic community through their research, teaching, and/or service. Applicants are requested to include in their cover letter information about how they will further this goal.

The University of Vermont is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, protected veteran status, or any other category legally protected by federal or state law. The University encourages applications from all individuals who will contribute to the diversity and excellence of the institution. Applications will be accepted until the positions are filled.

JOHNS HOPKINS UNIVERSITY POSTDOCTORAL RESEARCH FELLOWSHIPS IN SUBSTANCE ABUSE AND PSYCHOPHARMACOLOGY HUMAN RESEARCH TRAINING

Postdoctoral research fellowships available in a stimulating, productive program with excellent resources. Prepare to be an independent investigator.

HUMAN LABORATORY -- behavioral & clinical pharmacology of abused drugs (abuse liability, self-administration, cognitive/ memory function, impulsivity, neuroimaging); anti-drug abuse medication development; behavioral research related to addiction: delay discounting, behavioral economics, and sexual risk behavior. Opioids, cocaine, anxiolytics, alcohol, caffeine, nicotine, hallucinogens, psilocybin, salvinorin A, MDMA, methamphetamine.

CLINICAL TRIALS – testing medications, behavioral therapies (especially incentive/contingency-based), and combinations; psychiatric comorbidity research; addiction & pregnancy/women; therapeutic applications for
psilocybin (cancer anxiety & smoking cessation). Opioid, cocaine, tobacco, mixed/other dependencies

Eligibility: U.S. citizen, permanent resident. Many backgrounds are appropriate, including experimental or clinical psychology, pharmacology, psychiatry, neuroscience, public health, and social work. Background in human or nonhuman research is appropriate

NIH stipend levels: $37,000 to $51,000

Start Date: Flexible.

Faculty: George Bigelow, Roland Griffiths, Maxine Stitzer, Eric Strain, Kenneth Silverman, Robert Brooner, Miriam Mintzer, Uma McCann, Ryan Vandrey, Matthew Johnson, Kelly Dunn, David Thompkins, Denis Antoine, Fred Barrett

To apply: Contact George Bigelow; BPRU, Behavioral Biology Research Center; 5510 Nathan Shock Drive; Johns Hopkins Bayview Campus; Baltimore, Maryland 21224-6823. (410) 550-003, bigelow@jhmi.edu. For more information see www.bpru.org.

UNIVERSITY OF KENTUCKY, COLLEGE OF MEDICINE POSTDOCTORAL FELLOWSHIP

The University of Kentucky College of Medicine Department of Behavioral Science is seeking applicants for a postdoctoral fellowship. This is a two-year fellowship, with an optional third year, funded by National Institute on Drug Abuse (NIDA) T32 that is designed to train researchers in behavioral aspects of substance use disorders. The fellowship also provides ample opportunity for professional development, including grant writing and enhancing presentation and publication skills. Applicants should be highly motivated, have recently obtained a doctorate in psychology, pharmacology or a related discipline and must be a U.S. citizen or permanent resident. The fellowship includes salary, tuition (if applicable) and expenses for travel to conferences.

For further application details, please email Dr. Craig Mintzer (crush2@uky.edu).

UNIVERSITY OF CALIFORNIA, SAN DIEGO POSTDOCTORAL FELLOWSHIP

The Substance Abuse Research Program at the University of California, San Francisco is currently accepting applications to its two-year postdoctoral research training program. This program, funded by a National Institute on Drug Abuse (NIDA) T32 grant, aims to produce the next generation of leaders in the field of drug abuse treatment and services research. With the support of faculty mentors, scholars design and implement studies on treatment of drug and alcohol dependence. Current research interests of faculty include trials of efficacy and effectiveness of psychosocial and pharmacologic treatment of drug abuse, including:

- Tobacco dependence and food insecurity
- Innovative methodology including Internet-based studies
- Treatment of complex patients in innovative settings

- Diagnostic techniques and research on treatment tailored for HIV-positive drug abusers and drug abusers with psychiatric and medical disorders
- Provision of services to drug and alcohol abusing populations
- Instrument development in drug abuse

A variety of university-affiliated and community substance abuse programs are available as research sites. These include inpatient and outpatient settings programs that treat a range of problems related to drugs of abuse, including dependence on cocaine, nicotine, alcohol, and opiates. Our program encourages close research involvement with your preceptor, and involvement in selected classes, seminars, and grant preparation. Resources from other significant extramural funding and R01-level grants are also routinely available to scholars. Funds for travel and training opportunities are available.

More information can be found at: http://psych.ucsf.edu/SUDTSR

To Apply: Submit a cover letter, curriculum vitae, statement of research interests, and representative work or dissertation chapters, and 2 letters of reference to: jaime.smith@ucsf.edu. Applicants must have completed their doctoral degree and be a U.S. citizen or have Lawful Permanent Residency (green card) status at the time of appointment. Letters of reference should be sent directly from the recommenders to Ms. Adem.

Jaime Smith, CCRP, Division Administrator
Substance Abuse Research Program
ZSFG Psychiatry, UCSF School of Medicine
jaime.smith@ucsf.edu

UNIVERSITY OF CALIFORNIA, SAN DIEGO POSTDOCTORAL FELLOWSHIP

The Department of Family Medicine and Public Health at the University of California, San Diego is seeking a postdoctoral researcher in epidemiology, economics, and policy research on drug use and abuse. This position is funded through awards from TRDRP (Tobacco-related Disease Research Program) and NIH/NIDA (National Institute on Drug Abuse). The one- to three-year position is immediately available.

The selected fellow will work closely with Dr. Yu Yan Shi on projects about policy, economic, and neighborhood environments related to marijuana, tobacco, opioid, and other drugs. The candidate will also have opportunities to work with other inter-disciplinary researchers in the larger network of public health. Department of Family Medicine and Public Health at School of Medicine provides a multi-disciplinary and stimulating environment to prepare the candidate towards an independent career.

Applicants should have a doctorate in public health or social science (health services, health economics, health policy, community health, social work, behavioral medicine, psychology, epidemiology, urban studies, and other public health related fields). The ideal candidate will have strong quantitative skills, including prior experience in using statistical packages and analyzing large-scale population surveys or administrative records. Demonstrated ability to apply spatial analysis tools such as ArcGIS, or develop and
implement survey questionnaires, or design and implement behavioral economics experiments will be an advantage. Strong writing and communication skills are also expected.

The University of California, San Diego is an Equal Opportunity/Affirmative Action Employers. Minorities and women are strongly encouraged. U.S. citizen or permanent resident is preferred but not required. Visa sponsorship will be provided if needed. Applications will be considered until the position is filled. Interested candidates should submit a curriculum vitae, a cover letter describing research interests and experience, one writing sample, and three names of references to Dr. Yuyan Shi at yush001@ucsd.edu.

UNIVERSITY OF TEXAS, MCGOVERN MEDICAL SCHOOL
POSTDOCTORAL FELLOWSHIP

The Department of Psychiatry and Behavioral Sciences, UTHealth Medical School in Houston, is recruiting outstanding Ph.D. clinician scientists for Postdoctoral Fellowship opportunities. We seek well-trained, motivated individuals with excellent communication and interpersonal skills, demonstrated proficiency in scientific writing, and the desire to learn the necessary skills to transition into independent faculty positions. The training period involves two years starting in September or October 2019. A key focus for the training period will be the development of successful grant planning and writing skills pursuant to applications to NIH, NSF and private foundations.

NIH-funded investigators in the Department will serve as mentors. Current work focuses on treatment outcomes, clinical trials, behavioral interventions (Dr. Joy Schmitz), human behavioral processes, neuroimaging and psychopharmacology (Dr. Scott Lane), molecular, genetic/epigenetics (Dr. Consuelo Walsh-Bass), neuroimaging, cognitive neurosciences (Dr. Jair Soares), Bayesian statistics, data science, novel adaptive trial designs (Dr. Charles Green). Training and/or interest in any of these areas is welcomed, but we strongly emphasize team science and thus preference will be given to individuals seeking translational training across these domains. The department has strengths in clinical service and clinical research, particularly in the fields of substance use disorders and mood disorders. Our clinical research programs are housed at the state-of-the-art Behavioral and Biomedical Sciences Building (BBSB) and the UT Harris County Psychiatric Center, one of the largest inpatient academic psychiatric hospitals in the US with 250 acute care psychiatric beds.

UTHealth is an integral part of the Texas Medical Center (TMC), the largest medical center in the world, with a vibrant academic community and a plethora of outstanding collaborative and translational opportunities in the health sciences. Houston is the 4th largest US metropolitan area featuring continued growth and economic prosperity, vibrant opportunities, and a highly competitive cost of living relative to other culturally diverse metropolitan areas. Applicants must have completed a Ph.D or equivalent degree. Preference given to those with training or experience in programs with active NIH grant portfolios. Competitive salaries and benefits are available. To find out more information about these unique academically-driven positions or to apply, please forward a CV and letter of interest to Joy M. Schmitz, Ph.D., Professor and Director of the Center for Neurobehavioral Research on Addiction (CNRA), e-mail: Joy.M.Schmitz@uth.tmc.edu, phone: 713-486-2867, or Jair.C.Soares, M.D., Professor and Chair, e-mail: Jair.C.Soares@uth.tmc.edu, phone: 713-486-2507. The University of Texas Health Science Center at Houston is an EO/AA employer. M/F/D/V.

UNIVERSITY OF CALIFORNIA, LOS ANGELES
POSTDOCTORAL FELLOW

A position for Postdoctoral Research Fellow is available at the UCLA Addictions Laboratory (PI: Lara Ray). Our laboratory examines the clinical neuroscience of alcoholism, including studies of alcoholism etiology and treatment. Our focus is on translating basic science of addiction to clinically meaningful insights and interventions for clinical populations. Research methods employed include behavioral pharmacology, experimental psychopathology, neuroimaging, and clinical trials.

Postdoctoral fellows will be actively involved in data analysis, manuscript preparation, and development of independent extramural grant applications. Research qualifications include a PhD or MD degree in clinical psychology, psychiatry, neuroscience, or a related field. Preferred qualifications include significant experience with substance use research and sophistication in data analytic methods. Mentoring and professional development will be provided by Dr. Lara Ray and affiliated UCLA faculty members. Opportunities for teaching and mentoring of graduate and undergraduate students is available. Opportunities for clinical practice and licensure in clinical psychology are also available. UCLA is an Equal Opportunity Employer. Lab Website: https://addictions.psych.ucla.edu/

UNIVERSITY OF CALIFORNIA, LOS ANGELES
POSTDOCTORAL FELLOW

The UCLA Integrated Substance Abuse Programs (ISAP) invites applicants for a full-time post-doctoral position in a thriving research organization with decades of experience conducting clinical research on substance use disorders (SUDs). This position is available for an individual interested in interdisciplinary research on SUD topics, emphasizing experimental clinical trials to develop and test effective treatments for SUDs, with a focus on opioid use disorder. Opportunities in the rich research environment at UCLA include:

- numerous clinical trials on SUD treatment conducted by ISAP researchers and affiliated investigators at UCLA and across the nation;
- ISAP team involvement as prominent participants in the NIDA Clinical Trials Network;
- ongoing research focus on opioid use disorder (OUD), including studies on medication treatment for OUD and innovative delivery of OUD treatment;
- a focus on blending clinical practice and research, providing a rich setting in which to increase expertise in designing, conducting, and documenting clinical trials, as well as to learn skills in advanced methodologies applicable to clinical trials research.
Candidates should have a background in psychology, medicine, or neuroscience and be interested in developing expertise in clinical trials research involving pharmacotherapies and behavioral therapies for SUDs. Also of interest are candidates with expertise in implementation science and in statistical analysis that may be applied to clinical research on SUDs. Candidates must have:

- doctoral degree in psychology, medicine, public health, or social sciences;
- excellent writing and communication skills;
- ability to work in a fast-paced, collaborative research environment;
- ability to travel to clinical sites and interact with participants and clinical personnel.

Duration of the fellowship is flexible, initially for one year, with possible extension. Salary will be commensurate with experience and demonstrated capabilities in relevant areas, including writing for scholarly publications, familiarity with good research practices, and an understanding of ethical research and protection of human research participants.

Please send a cover letter, CV, and contact information for three references to:

Yih-Ing Hser, Ph.D. (yhser@mednet.ucla.edu)
Larissa Mooney, M.D. (lmooney@mednet.ucla.edu)

---

**Virginia Tech, Fralin Biomedical Research Institute Postdoctoral Associate**

Imagine working in a stimulating environment where you will be a part of cutting-edge research discoveries where

- multiple NIH grants fund a variety of diverse interdisciplinary and translational research projects
- invaluable grant-writing experience is gained and encouraged
- you will work closely with some of the leading researchers in addiction and behavioral economics
- you are encouraged to pitch your own ideas for meaningful research projects that fall within the scope of the lab
- postdoctoral associates average 5 published manuscripts per year

Imagine a growing research institute that attracts leading scientists from across the nation -- the Fralin Biomedical Research Institute at VTC (formerly known as the Virginia Tech Carilion Research Institute) is a unique public-private partnership that leverages Virginia Tech’s world-class strength in basic sciences, bioinformatics, and engineering with Carilion Clinic’s highly experienced medical staff and a rich history in medical education. Virginia Tech Carilion (VTC) improves human health and quality of life by providing leadership in medical education and biomedical and clinical research. This academic health center was recently renamed Fralin Biomedical Research Institute at VTC in honor of the $50 million donation provided by the generosity of Heywood and Cynthia Fralin to progress the growth of this institute and its contributions to medical and research advancements.

**Position Summary:** The Addiction Recovery Research Center (ARRC) is directed by Dr. Warren K. Bickel, an accomplished scholar and researcher whose work is frequently cited and receives national and international recognition. This position will work primarily on NIH funded projects that are providing new information about substance and alcohol use disorders, health behaviors, and decision-making. Several projects are focusing on the use of the Experimental Tobacco Marketplace to investigate choice behavior among nicotine users from a behavioral economics framework. Other projects are focusing on treatments for opioid use disorder and the examination of Episodic Future Thinking to improve health in individuals with prediabetes and other lifestyle related disorders. Moreover, ARRC has ongoing projects to examine the effects of Transcranial Magnetic Stimulation on cigarette smoking and overeating. The position is well suited for individuals interested in technological and behavioral economic applications to addiction and health behavior. This postdoctoral position will also be involved in developing pilot research programs in the research areas of the lab and will be expected to help develop these additional projects.

**Appointment:** 1-3 yrs.

**Eligibility:** Candidates are expected to have a solid background in psychology, behavioral economics, and/or addiction or health behaviors research. In addition, experience with behavior analysis and/or clinical trials is highly desirable. The successful candidate will possess a PhD in psychology, neuroscience, or appropriate related discipline and have a record of research excellence as indicated by peer-reviewed publications and presentations.

**Benefits:** Full-time annual salary, medical insurance coverage, and travel funds supported by NIH grants. Translational research training and career development opportunities are provided as part of this position.

**For more information:** Contact Ms. Patsy Marshall (patsym@vtc.vt.edu).

**To apply:** Send cover letter, curriculum vitae, statement of research interests, and 3 letters of reference to: Dr. Warren K. Bickel c/o Ms. Patsy Marshall (patsym@vtc.vt.edu). Applications will be reviewed on an ongoing basis.

**About us:** The Addiction Recovery Research Center (ARRC) was established in 2011 as part of the Virginia Tech Carilion Research Institute (VTCRI). The existing facilities and research teams are world-class and focus on transdisciplinary research on the scientific underpinnings of health and a range of diseases and substance use disorders. A new biomedical expansion is currently being constructed and will include additional research laboratories to focus on brain health and disorders, biomaterials-body device interfaces, cardiovascular sciences, cancer, metabolism and obesity, and infectious disease and immunity. The Fralin Biomedical Research Institute at VTC represents a new model for biomedical and behavioral science in which creative scientists can approach major problems with breadth and depth in a nurturing and intellectually challenging environment.

**About Roanoke, Virginia:** Roanoke, Virginia is located in Southwest Virginia in the foothills of the Appalachian Mountains and accessible by the Blue Ridge Parkway.
Roanoke is a vibrant community with an active downtown full of restaurants, theaters, museums, and an amphitheater that is home to many seasonal festivals and music events. Roanoke also offers great opportunities for an active outdoor lifestyle with 30 miles of greenway connecting charming neighborhoods and beautiful parks along the Roanoke River. Roanoke is one of two cities in the nation to earn the All-American City Award a record seven times.

GEISEL SCHOOL OF MEDICINE AT DARTMOUTH
ASSISTANT PROFESSOR

The Department of Biomedical Data Science at the Geisel School of Medicine at Dartmouth (Geisel) seeks outstanding applicants for a tenure-track Assistant Professor to join our faculty within the Center for Technology and Behavioral Health (CTBH). Exceptional candidates at the rank of Associate Professor may also be considered. Dartmouth is an R1: Doctoral University – Highest Research Activity in the Carnegie Classification, and faculty members benefit from highly collaborative and collegial interactions across campus, inclusive of departments at the Geisel School of Medicine, the College of Arts & Sciences, the Thayer School of Engineering and the Tuck School of Business.

CTBH is an interdisciplinary research group whose mission is to inform the optimal development, systematic evaluation, and sustainable implementation of digital therapeutics for behavioral health and health-care delivery transformation. Successful candidates will be pursuing a vigorous research program focused on the use of novel methodologies, intervention development, data analytics and/or biostatistics in digital health. Research focused on patient/consumer engagement, clinical effectiveness, or implementation of digital health behavior-change interventions will also be considered. That may include research in adaptive digital therapeutic interventions for health behavior change; development/refinement of analytic models for intensive, longitudinal mobile health data; digital phenotyping; or biostatistical analysis of densely sampled longitudinal data. Research designed to understand mechanisms of behavior change with digital health interventions is also of interest, as are interventions focusing on addictive behaviors. The activities of the center are diverse and inter-disciplinary; hence, the call for outstanding candidates from a breadth of different disciplines spanning behavioral medicine to biostatistics.

Applicants should have a PhD, MD, or equivalent degree with relevant post-doctoral training. Formal advanced training in behavioral science, research methods, biostatistics, data science, biomedical informatics, bioinformatics or a related field is preferred. Applicants should also have a successful track record of peer-reviewed publications, and ideally a history of extramural funding. Expectations for teaching and mentoring are a critical part of this role, and individuals will be provided with such opportunities through membership in relevant PhD graduate programs (e.g., Program in Quantitative Biomedical Sciences; Program in Experimental & Molecular Medicine, The Dartmouth Institute). Training grants in relevant areas (e.g., Science of Co-occurring Disorders, BD2K Predoctoral Training in Biomedical Big Data Science, the Burroughs Welcome training fund for Unifying Population and Laboratory-based Sciences) are available to support trainees in areas relevant to successful candidates.

Link to apply: https://apply.interfolio.com/60277

Contact for questions: Alan J. Budney, Ph.D.
mailto:alan.j.budney@dartmouth.edu

Geisel School of Medicine at Dartmouth
Center for Technology and Behavioral Health
46 Centerra Pkwy, Suite 315, HB 7255
Lebanon, NH 03766

UNIVERSITY OF FLORIDA
POSTDOCTORAL FELLOW

The Translational Science Training to Reduce the Impact of Alcohol on HIV infection is seeking a postdoctoral fellow. This is a multidisciplinary NIAAA T32 training program focused on alcohol and HIV Behavioral and clinical interventions, Data science, Neurocognition, and Brain Science. Postdocs will work on NIH-Funded grants, participate in seminars and training programs, and develop their own lines of research.

The state of Florida currently ranks second in new HIV infections per year, and second in total HIV/AIDS cases in the US. Alcohol consumption contributes to poor HIV outcomes and to ongoing HIV transmission, and the relationships between alcohol consumption and HIV can vary by age, gender, ethnicity, and sexual orientation, all of which is explored as part of this program of research.

The training program supports four pre-doctoral and two post-doctoral trainees at any time. Applications are accepted on a rolling basis based on availability of positions. Pre-doctoral trainees will be based in the following academic programs: Epidemiology, Biostatistics, Clinical and Health Psychology, Nursing Science, Health Education and Behavior, and the Interdisciplinary Program in Medicine. Funding includes an annual stipend, research/travel expenses and health insurance. Individuals from under represented populations are strongly encouraged to apply. The T32 program ensures appropriate depth in knowledge regarding alcohol, HIV, and several additional focus areas that represent areas of strength in ongoing research at UF:

- Behavioral Intervention
- Cognitive Science
- Data Science
- Epidemiology
- Microbiome
- Mhealth

If you have any questions or would like to apply, please email your CV to sharct32@phhp.ufl.edu
Division 28 Executive Committee

Elected Officers

- President: Ryan Vandrey
- Past President: Kelly Dunn
- President-Elect: Tom Gould
- Council Representative: William Stoops
- Members-at-Large: Eric Donny, Dustin Stairs, Cassie Gipson-Reichardt

Appointed Officers

- Secretary: Matt Kirkpatrick
- Treasurer: Will Aklin
- Newsletter Editor: Meredith Berry
- Divisional Awards: Richard Yi
- Membership: Brent Kaplan
- Fellows: Micky Koffarnus
- Program Chair (2021): Cecilia Bergeria
- Program Chair (2022): Jacob Borodovsky
- Finance Committee Chair: Andrew Huhn

Early Career Appointed Liaisons/Monitors

- Student Representative: Neo Gebru, Kathleen McNealy, Andrea Vasquez Ferreiro (social media chair)
- Early Career Psychologist Representative: Justin Strickland, Kirsten Smith
- Archivist: Justin Strickland

Appointed Liaisons/Monitors

- Board of Educational Affairs: M. Marlyne Kilbey
- Electronic Information: Ronald Wood
- Liaison to Committee on Animal Research and Ethics: Mark Smith
- Liaison to Division 55: M. Marlyne Kilbey
- Women’s Network Representative: Mary Cain
- Continuing Education Committee Chair: M. Marilyne Kilbey
- International Affairs Committee: Hendree Jones
- Liaison to Division 50: Linda Sobell
- Liaison to Science Directorate: Rick Bevins
- Liaison to the Board for the Advancement of Psychology in the Public Interest: Martin Iguchi